T1	HMM 310 316	safety
T2	HMM 325 339	immunogenicity
T3	HMM 669 675	Safety
T4	HMM 719 766	Varicella-zoster virus (VZV) antibody responses
T5	HMM 875 922	VZV antibody geometric mean titer (GMT; day 28)
T6	HMM 928 980	VZV antibody geometric mean rise (GMR; days 1 to 28)
T7	HMM 990 1052	incidence of vaccine-related serious adverse experiences (AEs)
T8	HMM 1144 1148	GMTs
T9	HMM 1203 1268	estimated GMT ratio (refrigerated formulation/frozen formulation)
T10	HMM 1323 1327	GMRs
T11	HMM 1369 1396	vaccine-related serious AEs
T12	HMM 1436 1451	safety profiles
T13	HMM 1500 1533	frequencies of injection-site AEs
T14	HMM 1670 1697	frequencies of systemic AEs
T15	HMM 1743 1762	vaccine-related AEs
T16	HMM 1867 1881	safety profile
T17	HMM 1892 1903	immunogenic
